TY  - JOUR
TI  - Comparison of Clinical, Pathological, and Prognostic Features in BRCA Mutant and Wild-Type Male Breast Cancer Patients
AB  - Objective: Published studies on male breast cancer (MBC) and BRCA mutations are scarce and usually include,  a small number of patients. The clinicopathological characteristics of BRCA mutant and wild-type MBC patients were compared in more than forty patients in this study. Materials and Methods: A retrospective review of MBC patients’ clinical and histopathological data was conducted. To compare the patients’ characteristics, chi-square test and Fisher's Exact test were utilized. Kaplan–Meier analysis was used to examine the survival analysis. Results: In total 43 cases were reviewed. The average duration of follow-up was 35.8 months. BRCA mutations were found in 11 (25.6%) of the patients. BRCA1 mutations were found in four patients (9.3%), BRCA2 mutations in six patients (14%), and BRCA1 and BRCA2 mutations in one patient (2.3%). The median age at diagnosis was 58 years old, and there was no statistically significant difference between groups (p = 0.7). Tumor location (p = 0.3), human epidermal growth factor receptor 2 overexpression (p = 0.5), estrogen receptor status (p = 0.05), progesterone receptor status (p = 0.6), tumor stage (p = 0.9), lymph node positivity ( p = 0.5), tumor histology ( p = 0.06), and recurrence status ( p = 0.6) were similar between BRCA-wild type and -mutated patients. Overall survival averaged 115.6 months (range: 76.0–155.3), with no statistically significant differences between groups (p = 0.6). Conclusion: This study investigated clinical and pathological characteristics and prognoses of BRCA wild and mutant-type MBC and these were similar in all groups studied.
AU  - Dogan, Izzet
AU  - YAZICI, HÜLYA
AU  - Saip, Pınar
AU  - AYDIN SUDABATMAZ, ESRA
DO  - 10.4274/ejbh.galenos.2022.2022-5-2
PY  - 2022
JO  - European Journal of Breast Health
VL  - 18
IS  - 4
SN  - 2587-0831
SP  - 323
EP  - 328
DB  - TRDizin
UR  - http://search/yayin/detay/1130519
ER  -